Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report

Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report

Background and Aim: Approximately 60% of glioblastoma multiforme (GBM) patients possess an unmethylated O-6-methylguanine-DNA methyltransferase (MGMT) gene, which confers a limited response to standard-of-care treatment with temozolomide (TMZ), resulting in a lower survival. Dianhydrogalactitol (VAL...

Full description

Bibliographic Details
Main Authors: Chengcheng Guo, Qunying Yang, Jiawei Li, Shaoxiong Wu, Meiling Deng, Xiaojing Du, Ke Sai, Xiaobing Jiang, Zhenghe Chen, Ji Zhang, Fuhua Lin, Jian Wang, Yinsheng Chen, Chao Ke, Xiangheng Zhang, Xue Ju, Yonggao Mou, Jeffrey Bacha, Anne Steino, Sarath Kanekal, Claire Kwan, Gregory Johnson, Richard Schwartz, John Langlands, Dennis Brown, Zhong-ping Chen
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Glioma
Subjects:
adjuvant
chemotherapy
dianhydrogalactitol
glioblastoma multiforme
o-6-methylguanine-dna methyltransferase
phase 2
stupp regimen
temozolomide
Online Access:http://www.jglioma.com/article.asp?issn=2589-6113;year=2019;volume=2;issue=4;spage=167;epage=173;aulast=Guo

Internet

http://www.jglioma.com/article.asp?issn=2589-6113;year=2019;volume=2;issue=4;spage=167;epage=173;aulast=Guo

Similar Items